| Detailed information |
|---|
| CancerLivER ID | 2102 |
| Biomarker | CPE |
| Biomarker Name/Symbol (given in Publication) | CPE |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Biomarker for predicting tumor recurrence in HCC patients who are in the early pathology stage and able to receive curative resection; but not validated on independent dataset |
| Experimental Condition | Recurrence between stage-I v/s stage-II |
| Cancer type | Hepatocellular carcinoma |
| Regulation | CPE expression level was also significantly correlated with the tumor recurrence for both stage i.e. Stage-I and Stage-II |
| Level of significance | p < 0.01 |
| Source | Tissue |
| PMID | 26803519 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | 120 HCC patients (70 stage I patients and 50 stage II patients) from Taiwan Liver Cancer Network (TLCN) along with their clinical data in year 2010. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human HCC |
| Year of Publication | 2016 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |